QuidelOrtho develops and manufactures diagnostic technologies spanning immunoassay, molecular diagnostics, rapid antigen and point-of-care testing for labs, clinics and home use.
QuidelOrtho is a pure-play diagnostics company formed in 2022 through the combination of Quidel Corporation and Ortho Clinical Diagnostics. It develops and manufactures technologies for diagnostic testing across the healthcare continuum, from home and self-testing through point-of-care settings, clinical laboratories and transfusion medicine. The company operates globally and claims more than 120 years of collective experience in diagnostics between the two merged organisations.
Its technical work spans immunoassay, molecular diagnostics, PCR assays, lateral-flow assay technology, rapid antigen testing and point-of-care testing. The product portfolio covers infectious disease testing for conditions including HIV, hepatitis C, influenza, strep and COVID-19, in addition to transfusion medicine and clinical laboratory solutions.
The company's engineering record includes a number of early or first-in-class products: among the earliest lateral-flow pregnancy test strips, the first FDA-approved rapid antigen diagnostic test for influenza, and one of the earliest molecular PCR assays for detecting SARS-CoV-2. QuidelOrtho describes its mission as raising the performance of diagnostic testing to detect disease and health conditions, and providing vital health information when and where it is needed.
